Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Cardiovascular diseases

Semaglutide reduces cardiovascular risk across risk subgroups

GLP-1 agonist semaglutide significantly decreases risk of cardiovascular events and death across different risk groups of patients with type 2 diabetes, secondary analysis of clinical trial data has found.

GLP-1 Glucagon like peptide

Source: Alamy

Post-hoc analyses provides further evidence that GLP-1 receptor agonist semaglutide decreases risk of cardiovascular events in people with type 2 diabetes

The GLP-1 receptor agonist semaglutide (Ozempic; Novo Nordisk) reduces the risk of major cardiovascular events across patients with type 2 diabetes mellitus regardless of their baseline cardiovascular risk level, a secondary analysis of trial data has found[1].

Researchers looked at data from a trial involving 3,297 people with type 2 diabetes and either clinical or subclinical cardiovascular disease. They were randomly assigned to either semaglutide (0.5mg/week or 1.0mg/week) or placebo, plus usual care.

Over a median follow-up of 2.1 years, the overall reduction in risk of major cardiovascular events was 26%. The researchers found that there was no significant difference in risk reduction between those with a prior history of myocardial infarction or stroke and those without, nor between those with established cardiovascular disease and those without.

“The results of these post-hoc analyses provide further evidence of the consistent cardiovascular risk reduction [of semaglutide] in people with type 2 diabetes,” said lead author Stephen Bain, who presented the results at the European Society of Cardiology Congress in Munich, Germany, on 25–29 August 2018.

Semaglutide was authorised by the European Medicines Agency in February 2018, but is not yet available in the UK.


Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205530

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.